^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    EGFR exon 21 mutation

    i
    Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor
    Entrez ID:
    1956
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Apply
    Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC (LUN 17-139) (NCT03786692)
    Phase 2
    Fox Chase Cancer Center
    Recruiting
    Last update posted :
    02/12/2024
    Initiation :
    09/04/2019
    Primary completion :
    01/01/2025
    Completion :
    01/01/2027
    PD-L1 • ALK • ROS1
    |
    EGFR mutation • ALK rearrangement • EGFR exon 21 mutation • ROS1 rearrangement • EGFR exon 18 mutation
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • pemetrexed
    Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer (NCT05104281)
    Phase 3
    Qingdao Central Hospital
    Recruiting
    Last update posted :
    03/29/2023
    Initiation :
    01/01/2021
    Primary completion :
    12/31/2023
    Completion :
    12/31/2024
    EGFR
    |
    EGFR mutation • EGFR exon 21 mutation • EGFR exon 18 mutation
    |
    Avastin (bevacizumab) • Tagrisso (osimertinib)
    BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC) (NCT01562028)
    Phase 2
    ETOP IBCSG Partners Foundation
    Completed
    Last update posted :
    08/24/2022
    Initiation :
    06/01/2012
    Primary completion :
    10/31/2018
    Completion :
    10/31/2018
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 21 mutation
    |
    Avastin (bevacizumab) • erlotinib
    Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR Mutations (NCT01470716)
    Phase 2
    National Cancer Center, Korea
    Active, not recruiting
    Last update posted :
    04/06/2022
    Initiation :
    01/01/2012
    Primary completion :
    12/31/2021
    Completion :
    06/30/2022
    EGFR
    |
    EGFR mutation • EGFR exon 21 mutation
    |
    erlotinib
    EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC (secgolc004) (NCT03720873)
    Phase 2
    Fujian Cancer Hospital
    Unknown status
    Last update posted :
    10/25/2018
    Initiation :
    10/01/2018
    Primary completion :
    06/01/2021
    Completion :
    09/01/2022
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 21 mutation
    |
    erlotinib • gefitinib • Focus V (anlotinib) • Conmana (icotinib)
    Gefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR Mutation (Geber) (NCT03486496)
    Phase 2
    Fujian Cancer Hospital
    Unknown status
    Last update posted :
    04/03/2018
    Initiation :
    06/05/2018
    Primary completion :
    06/01/2019
    Completion :
    02/01/2020
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 21 mutation
    |
    gefitinib
    Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 Mutations (NCT01024413)
    Phase 3
    Chinese Society of Lung Cancer
    Completed
    Last update posted :
    03/01/2017
    Initiation :
    07/01/2009
    Primary completion :
    06/01/2015
    Completion :
    06/01/2015
    EGFR
    |
    EGFR mutation • EGFR exon 21 mutation • EGFR positive
    |
    erlotinib • gefitinib